摘要 |
The present invention relates to compounds with the formula (I), or a pharmaceutically acceptable salt thereof, wherein: R1 is selected from the group consisting of (C1-C6)alkyl, -(CR3R4)t(C3-C12)cycloalkyl, -(CR3R4)t(C6- C12)aryl, and -(CR3R4)t(4-10)-membered heterocyclyl; b and k are each independently selected from 1 and 2; j is selected from the group consisting of 0, 1, and 2; t, u, p, q, and v are each independently selected from the group consisting of 0, 1, 2, 3, 4, and 5; T is a (6-10)-membered heterocycly l containing at least one nitrogen atom; R2 is selected from the group consisting of H, (C1-C6)alkyl, -(CR3R4)t(C3-C12)cycloalkyl, -(CR3R4)t(C6- C12)aryl, and -(CR3R4)t(4-10)-membered heterocyclyl; each R3 and R4 is independently selected from H and (C1-C6)alkyl, the carbon atoms of T, R1, R 2, R3 and R4 may each be optionally, substituted by I to 5 R5 groups; R5 is defined in the claims; The compounds of the present invention are 11 .szlig. - hsd-1 inhibitors, and are therefore believed to be useful in the treatment o f diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders, depression, hypertension, and metabolic diseases.
|
申请人 |
PFIZER LIMITED |
发明人 |
CHENG, HENGMIAO;CRIPPS, STEPHAN JAMES;WANG, YONG;EDWARDS, MARTIN PAUL;JOHNSON, THEODORE OTTO, JR.;NAIR, SAJIV KRISHNAN;SMITH, CHRISTOPHER RONALD;TAYLOR, WENDY DIANNE;SIU, MICHAEL |